21st century glaucoma care.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
03
07
2018
accepted:
07
08
2018
revised:
31
07
2018
pubmed:
12
10
2018
medline:
5
7
2019
entrez:
12
10
2018
Statut:
ppublish
Résumé
Glaucoma care has evolved dramatically over the past generation, with changes that have incorporated new technology and improved understanding of the disease process. A major need is to construct a useful definition of glaucomatous optic neuropathy that can be used to compare data across clinical research studies. The treatment of glaucoma should now be based on achievement of a goal target for intraocular pressure, unique to each patient. Adherence with eye drop treatment is far from ideal and can be improved using reminder systems. Sustained delivery of glaucoma medication is on the horizon. New surgical approaches to glaucoma are being actively studied but have not as yet found their place in its care, with rigorous testing against present treatments needed.
Identifiants
pubmed: 30305707
doi: 10.1038/s41433-018-0227-8
pii: 10.1038/s41433-018-0227-8
pmc: PMC6367343
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
254-260Références
Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86:238–42.
pubmed: 11815354
pmcid: 11815354
Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. Manag Sci. 1963;9:458–67.
doi: 10.1287/mnsc.9.3.458
Arora KS, Robin AL, Corcoran KJ, Corcoran SL, Ramulu PY. Use of various glaucoma surgeries and procedures in Medicare beneficiaries from 1994 to 2012. Ophthalmology. 2015;122:1615–24.
doi: 10.1016/j.ophtha.2015.04.015
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90.
doi: 10.1016/j.ophtha.2014.05.013
Shiose Y, Kitazawa Y, Tsukahara S, Akamatsu T, Mizokami K, Futa R, et al. Epidemiology of glaucoma in Japan - a nationwide glaucoma survey. Jpn J Ophthalmol. 1991;35:133–55.
pubmed: 1779484
Brandt JD, Beiser JA, Kass MA, Gordon MO. Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001;108:1779–88.
doi: 10.1016/S0161-6420(01)00760-6
Brandt JD. Corneal thickness in glaucoma screening, diagnosis, and management. Curr Opin Ophthalmol. 2004;15:85–89.
doi: 10.1097/00055735-200404000-00004
Broman AT, Quigley HA, West SK, Katz J, Munoz B, Bandeen-Roche K, et al. Estimating the rate of progressive visual field damage among those with open-angle glaucoma from cross-sectional data. Invest Ophthalmol Vis Sci. 2008;49:66–76.
doi: 10.1167/iovs.07-0866
Jampel HD. Target pressure in glaucoma therapy. J Glaucoma. 1997;6:133–8.
doi: 10.1097/00061198-199704000-00010
Gordon MO, Kass MA, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573–83.
doi: 10.1001/archopht.117.5.573
Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK. Visual field progression in the Collaborative Initial Glaucoma Treatment Study: the impact of treatment and other baseline factors. Ophthalmology. 2009;116:200–7.
doi: 10.1016/j.ophtha.2008.08.051
Realini T, Vickers WR. Symmetry of fellow-eye intraocular pressure responses to topical glaucoma medications. Ophthalmology. 2005;112:599–602.
doi: 10.1016/j.ophtha.2004.11.028
De Moraes CG, Mansouri K, Liebmann JM, Ritch R, Triggerfish Consortium. Association between 24-hour intraocular pressure monitored with contact lens sensor and visual field progression in older adults with glaucoma. JAMA Ophthalmol 2018. https://doi.org/10.1001/jamaophthalmol.2018.1746 .
doi: 10.1001/jamaophthalmol.2018.1746
Jensen AD, Maumenee AE. Home tonometry. Am J Ophthalmol. 1973;76:929–32.
doi: 10.1016/0002-9394(73)90084-6
Mudie LI, LaBarre S, Varadaraj V, Karakus S, Onnela J, Munoz B, et al. The Icare HOME (TA022) Study: performance of an intraocular pressure measuring device for self-tonometry by glaucoma patients. Ophthalmology. 2016;123:1675–84.
doi: 10.1016/j.ophtha.2016.04.044
Friedman DS, Nordstrom BL, Mozaffari E, Quigley HA. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005;112:1500–4.
doi: 10.1016/j.ophtha.2005.02.030
Boland MV, Chang DS, Frazier T, Plyler R, Jefferys JL, Friedman DS. Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the automated dosing reminder study. JAMA Ophthalmol. 2014;132:845–50.
doi: 10.1001/jamaophthalmol.2014.857
Varadaraj V, Kahook MY, Ramulu PY, Pitha IF. Patient acceptance of sustained glaucoma treatment strategies. J Glaucoma. 2018;27:328–35.
doi: 10.1097/IJG.0000000000000913
Brandt JD, DuBiner HB, Benza R, Sall KN, Walker GA, Semba CP, et al. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmology. 2017;124:1565–6.
doi: 10.1016/j.ophtha.2017.04.022
Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am J Ophthalmol. 2017;175:137–47.
doi: 10.1016/j.ajo.2016.11.020
Natarajan JV, Chattopadhyay S, Ang M, Darwitan A, Foo S, Zhen M, et al. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS ONE. 2011;6:e24513.
doi: 10.1371/journal.pone.0024513
Pitha I, Kimball EC, Oglesby EN, Pease ME, Fu J, Schaub J, et al. Sustained dorzolamide release prevents axonal and retinal ganglion cell loss in a rat model of IOP-glaucoma. Transl Vis Sci Technol. 2018;7:13.
doi: 10.1167/tvst.7.2.13
Quigley HA, Park CK, Tracey PA, Pollack IP. Community screening for eye disease by lay persons: the Hoffberger program. Am J Ophthalmol. 2002;133:386–92.
doi: 10.1016/S0002-9394(01)01380-0
Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83:711–6.
doi: 10.2105/AJPH.83.5.711
Kavitha S, Zebardast N, Palaniswamy K, Wojciechowski R, Chan ES, Friedman DS, et al. Family history is a strong risk factor for prevalent angle closure in a South Indian population. Ophthalmology. 2014;121:2091–7.
doi: 10.1016/j.ophtha.2014.05.001
Van Coevorden RE, Mills RP, Chen YY, Barnebey HS. Continuous visual field test supervision may not always be necessary. Ophthalmology. 1999;106:178–81.
doi: 10.1016/S0161-6420(99)90016-7
Liu MM, Cho C, Jefferys JL, Quigley HA, Scott AW. Use of optical coherence tomography by nonexpert personnel as a screening approach for glaucoma. J Glaucoma. 2018;27:64–70.
doi: 10.1097/IJG.0000000000000822
Chauhan BC, Malik R, Shuba LM, Rafuse PE, Nicolela MT, Artes PH. Rates of glaucomatous visual field change in a large clinical population. Invest Ophthalmol Vis Sci. 2014;55:4135–43.
doi: 10.1167/iovs.14-14643
Chauhan BC, Garway-Heath DF, Goñi FJ, Rossetti L, Bengtsson L, Viswanathan B, et al. A. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol. 2008;92:569–73.
doi: 10.1136/bjo.2007.135012
Matsumoto C, Yamao S, Nomoto H, Takada S, Okuyama S, Kimura S, et al. Visual field testing with head-mounted perimeter ‘imo’. PLoS ONE. 2016;11:e0161974.
doi: 10.1371/journal.pone.0161974
Wu Z, Weng DSD, Rajshekhar R, Thenappan A, Ritch R, Hood DC. Evaluation of a qualitative approach for detecting glaucomatous progression using wide-field optical coherence tomography scans. Transl Vis Sci Technol. 2018;7:5.
doi: 10.1167/tvst.7.3.5
Schuman JS, Hee MR, Arya AV, Pedut-Kloizman T, Puliafito CA, Fujimoto JG, et al. Optical coherence tomography: a new tool for glaucoma diagnosis. Curr Opin Ophthalmol. 1995;6:89–95.
doi: 10.1097/00055735-199504000-00014
Cordeiro MF, Normando EM, Cardoso MJ, Miodragovic S, Jeylani S, Davis BM, et al. Real-time imaging of single neuronal cell apoptosis in patients with glaucoma. Brain. 2017;140:1757–67.
doi: 10.1093/brain/awx088
Welsbie DS, Yang Z, Ge Y, Mitchell KL, Zhou X, Martin SE, et al. Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci USA. 2013;110:4045–50.
doi: 10.1073/pnas.1211284110
Quigley H, Arora K, Idrees S, Solano F, Bedrood S, Lee C, et al. Biomechanical responses of lamina cribrosa to intraocular pressure change assessed by optical coherence tomography in glaucoma eyes. Invest Ophthalmol Vis Sci. 2017;58:2566–77.
doi: 10.1167/iovs.16-21321
Gedde SJ, Feuer WJ, Shi W, Lim KS, Barton K, Goyal S, et al. Treatment outcomes in the Primary Tube Versus Trabeculectomy Study after 1 year of follow-up. Ophthalmology. 2018;125:650–63.
doi: 10.1016/j.ophtha.2018.02.003
Quigley HA. Clinical trials for glaucoma neuroprotection are not impossible. Curr Opin Ophthalmol. 2012;23:144–54.
doi: 10.1097/ICU.0b013e32834ff490